Liver Disease Diagnostics Market is estimated to be US$ 55.73 billion by 2030 with a CAGR of 6.1% during the forecast period

Liver Disease Diagnostics Market accounted for US$ 30.96 billion in 2020 and is estimated to be US$ 55.73 billion by 2030 and is anticipated to register a CAGR of 6.1%. Diagnostics for liver illness include a variety of tests that can help determine the status of the liver. The liver aids in the distribution of blood and processes throughout the body. It also aids in the coagulation of proteins in the blood, the detoxification of harmful compounds, and the usage of supplements. Due to the existence of unique chemicals in liver cells, liver cells can execute synthetic responses. When cells die, these chemicals are released into the bloodstream, allowing for easier dissection during liver capacity testing. Infectious, immunological, genetic, and metabolic factors all have a role in the development of liver illnesses. Diseases have a variety of origins, making diagnosis difficult. As a result, multiple tests must be performed in order to accurately diagnose the disease's source. If a patient has liver disease, they may have symptoms such as fatigue, weakness, and nausea.

The report " Global Liver Disease Diagnostics Market, By Diagnosis Technique (Imaging, Laboratory Tests, Endoscopy, Biopsy, Others), End-use (Hospital, Laboratories, Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030''

Key Highlights:

- TAEUS FLIP system acquired CE certification from ENDRA Life Sciences Inc. in March 2020. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis are diagnosed and monitored using this technique, which analyses liver fat (NASH). It's an ultrasound technology that measures fat in the liver accurately and at the point of care.

Analyst View:

The market for liver disease diagnostics is expected to grow due to increased efforts by key companies to develop highly sensitive and quick tests to detect liver illnesses in specific populations such as pregnant women and HIV-positive individuals. For instance, Abbott got a CE mark in February 2019 for the Determine HBsAg 2 test, a sensitive, easy-to-use, and quick diagnostic test for hepatitis B. The market is expected to be driven by companies focusing on collaborations and partnerships to improve the quality of care. For example, Perspectum Diagnostics and Precious Medical Center in Singapore partnered in October 2019 to deliver LiverMultiScan. The goal of this collaboration was to raise public awareness about the importance of liver screening as part of routine health checks. Market expansion is likely to be fueled by researchers undertaking studies to promote the development of novel diagnostic methods that can accurately identify between benign and malignant tumours. For instance, Charité - Universitätsmedizin Berlin researchers employed tomoelastography to examine tumour mechanical properties and developed a new Magnetic Resonance Imaging (MRI) technique to detect tumour consistency grading.

To know the upcoming trends and insights prevalent in this market, click the link below:

Key Market Insights from the report:

Global Liver Disease Diagnostics Market accounted for US$ 30.96 billion in 2020 and is estimated to be US$ 55.73 billion by 2030 and is anticipated to register a CAGR of 6.1%. The Global Liver Disease Diagnostics Market is segmented based on diagnosis technique, end-user and region.

- Based on Diagnosis Technique, Global Liver Disease Diagnostics Market is segmented into Imaging, Laboratory Tests, Endoscopy, Biopsy, Others.
- Based on End-User, Global Liver Disease Diagnostics Market is segmented into Hospital, Laboratories, Others.
- By Region, the Global Liver Disease Diagnostics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Global Liver Disease Diagnostics Market:

The key players operating in the liver disease diagnostics market are Abbott, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Randox Laboratories Ltd., Boston Scientific Corporation, Laboratory Corporation of America Holdings, Fujifilm Corporation, Horiba Medical and Siemens Healthcare GmbH. Multiple strategies for the development of novel technologies to advance patient care are being implemented by the key players. BTG plc was acquired by Boston Scientific Corporation in August 2019 to provide access to sophisticated technology for better patient care.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.